Real‐world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer

E-ISSN： 1464-410x|121|2|268-274

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.121, Iss.2, 2018-02, pp. : 268-274

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Improvement of Safety Profile of Docetaxel by Weekly Administration in Patients with Metastatic Breast Cancer

Oncology Research and Treatment, Vol. 30, Iss. 8-9, 2007-09 ,pp. : 436-441

Karger

Access to resources Recommend Favorite

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer

CANCER, Vol. 119, Iss. 20, 2013-10 ,pp. : 3636-3643

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

THE PROSTATE, Vol. 75, Iss. 8, 2015-06 ,pp. : 836-844

John Wiley & Sons Inc

Access to resources Recommend Favorite

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

Oncology Research and Treatment, Vol. 30, Iss. 7, 2007-06 ,pp. : 355-360

Karger

Access to resources Recommend Favorite

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 281-287

Karger

Access to resources Recommend Favorite